IAVI Report

In conversation with four experts who are applying lessons from the decades-long battle against HIV/AIDS to the ongoing COVID-19 pandemic.

John Nkengasong warns against complacency setting in as vaccines trickle into many African countries.

Researchers describe the experimental HIV vaccine approach called germline targeting as “shepherding” the immune system. They hope it will lead to greener pastures.

The last time I penned a letter in this publication, nearly a year ago, I closed by saying: “If science is our best hope, we are in good hands.” That certainly proved to be the case. There are now three authorized COVID-19 vaccines in the U.S., and seven that have received an Emergency Use Listing…

How will the results from recent trials set the course for future research?

SARS-CoV-2 is the first Disease X. There will certainly be others. Will the world be better prepared for the next one?

An interview with Seth Berkley, chief executive officer of Gavi, the Vaccine Alliance

Numerous monoclonal antibodies are already in development for both treatment and prevention. There are many unanswered questions, but, if they work, antibodies may play a role in ending this pandemic and in responding to future viral outbreaks.

Scientists are applying decades of HIV research experience to the development of SARS-CoV-2 vaccines in the race to end the pandemic.

When Bill Gates delivered a TED talk in 2015, he warned that the world was not ready for the next pandemic. Many others have issued similar warnings, some on the pages of this publication. Vanity Fair recently referred to Gates, Mike Osterholm, and Seth Berkley (see Finding a global solution for a global problem), among…

Linda-Gail Bekker talks about how she came to work on HIV and shares her thoughts on an evolving field.

Paul Stoffels of Johnson & Johnson talks about the company’s broad HIV portfolio and the role of industry in advancing vaccine research.